Given the ability of CD40-stimulating antibodies to promote DC function and the association of intratumoral DCs with T cell infiltration, it is encouraging that anti-CD40 infusion, in combination with IL-2 infusion, supports the antitumor activity of melanoma-specific TCR transgenic T cells in an IL-12- and CD80/CD86-dependent manner [71] and potentially involves CD70 [72]. Here, CD40 is linked to melanoma.